Furthermore, patient-sourced, in vitro organoid system will be utilized and whole exome sequencing and bulk RNA sequencing are undergoing to investigate the hypothesis that HDAC inhibition can alter the neoantigen landscape, promoting the expression of cancer neoantigens and expanding neoantigen-specific responses by the host immune system. This evidence concerns the gene HDAC9 and cancer.